The U.S. Food and Drug Administration (FDA) has given its seal of approval to Veozah, a groundbreaking medication manufactured by Astellas Pharma. Designed to combat hot flashes experienced by women during menopause, Veozah is a once-a-day pill targeting moderate-to-severe symptoms such as sweating, flushing, and chills. By focusing on brain connections that regulate body temperature, this innovative approach offers women a new safe and effective treatment option, according to the FDA.

Hot flashes affect a significant majority—over 80%—of women undergoing menopause. This natural process typically occurs between the ages of 45 and 55 when the body gradually decreases its production of reproductive hormones. Hormonal pills that elevate estrogen and progestin levels are commonly prescribed to alleviate hot flashes. However, this treatment may not be suitable for all women, especially those with a history of stroke, blood clots, heart attack, or other underlying health conditions. Extensive research indicates that hormone-based therapies can heighten the risk of recurring health problems, although the specific level of risk varies based on individual circumstances.

It is important to note that Veozah does come with a cautionary note regarding potential liver damage. The FDA emphasizes the need for comprehensive screening before prescribing the medication to ensure the patient’s liver health. Regular blood tests during the treatment period will enable close monitoring and prompt detection of any safety concerns. This precaution underscores the FDA’s commitment to patient safety and underscores the importance of close medical supervision throughout the course of treatment.

In contrast to hormonal treatments, Veozah, the newly approved pill, does not contain any hormones. Nevertheless, it carries an important warning from the FDA regarding potential liver damage. Prior to receiving a prescription, women must undergo screening for liver damage or infection. Additionally, they will be required to have blood tests conducted every three months over a nine-month period to closely monitor safety concerns, as outlined by the FDA label.

Astellas has disclosed that Veozah will have a price tag of $550 for a one-month supply. It’s worth noting that this figure does not account for insurance coverage or potential discounts typically negotiated by insurers and pharmacy benefit managers.

The approval of Veozah represents a significant milestone in women’s health, providing a much-needed solution for managing hot flashes during menopause. With its novel approach and focus on addressing the underlying cause of symptoms, Veozah offers hope and improved quality of life for women navigating this transformative stage. As more women gain access to this new treatment option, it is anticipated that Veozah will make a positive impact in the lives of those seeking relief from menopausal hot flashes.